Prevalence of coeliac disease in patients with systemic lupus erythematosus: a systematic review and meta-analysis

Lupus Sci Med. 2024 Feb 13;11(1):e001106. doi: 10.1136/lupus-2023-001106.

Abstract

Background: There is some evidence of a higher prevalence of coeliac disease (CD) among patients with SLE than in the general population. However, the prevalence estimates vary substantially.

Objective: To investigate the prevalence of CD among patients with SLE through systematic review and meta-analysis.

Methods: We performed searches in the databases of Medline, Embase, Cochrane and Web of Science Core Collection between 1 January 1990 and 9 July 2023. A total of 2053 publications were rendered in the searches, of which 68 were reviewed in full text and 14 included in the analyses. Primary analysis estimated the pooled prevalence of biopsy-verified CD in patients with SLE. In the secondary analysis, the prevalence of serological markers indicative of CD was investigated. The quality of studies was appraised using the Joanna Briggs Institute Critical Appraisal Tool. We conducted meta-regression analyses to investigate associations between the prevalence of CD in individuals with SLE and publication year, study population size, CD prevalence in the general population, proportion of females and quality assessment score.

Results: A total of 14 studies met the inclusion criteria, of which 11 were included in the primary analysis of biopsy-verified CD. Among 1238 patients with SLE, 14 had CD. The weighted pooled prevalence of CD was 0.7% (95% CI 0.0 to 1.8). The weighted pooled prevalence of CD serological markers in 1063 patients with SLE was 3.7% (95% CI 1.4 to 6.7). In meta-regression analyses, no associations between CD prevalence and study characteristics, demographics and quality assessment scores were found.

Conclusions: In this meta-analysis, we found a weighted pooled prevalence of biopsy-verified CD in patients with SLE comparable with the prevalence in the general population. Our findings do not support routine screening for CD in patients with SLE. However, individual screening could be considered in cases of clinical suspicion and additional risk factors for CD.

Prospero registration number: CRD42022339594.

Keywords: Antibodies; Autoimmune Diseases; Epidemiology; Lupus Erythematosus, Systemic; Prevalence.

Publication types

  • Meta-Analysis
  • Systematic Review

MeSH terms

  • Biopsy
  • Celiac Disease* / complications
  • Celiac Disease* / diagnosis
  • Celiac Disease* / epidemiology
  • Female
  • Humans
  • Lupus Erythematosus, Systemic* / complications
  • Lupus Erythematosus, Systemic* / epidemiology
  • Prevalence
  • Risk Factors